PsyBio Therapeutics Corp.
PSYBF · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 6/30/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $2 | $2 | $0 |
| Gross Profit | -$0 | -$2 | -$2 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $1 | $0 | $0 |
| G&A Expenses | $4 | $9 | $1 | $0 |
| SG&A Expenses | $4 | $9 | $5 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $4 | $0 |
| Other Operating Expenses | -$0 | -$2 | -$0 | $0 |
| Operating Expenses | $4 | $7 | $5 | $0 |
| Operating Income | -$4 | -$9 | -$6 | -$0 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$1 | -$2 | $0 | $0 |
| Pre-Tax Income | -$5 | -$11 | -$6 | -$0 |
| Tax Expense | $0 | $1 | $0 | $0 |
| Net Income | -$5 | -$11 | -$6 | -$0 |
| % Margin | – | – | – | – |
| EPS | -0.042 | -0.1 | -0.2 | 0 |
| % Growth | 58% | 50% | – | – |
| EPS Diluted | -0.042 | -0.1 | -0.2 | 0 |
| Weighted Avg Shares Out | 112 | 107 | 32 | 0 |
| Weighted Avg Shares Out Dil | 112 | 107 | 32 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $9 | $6 | $0 |
| EBITDA | -$5 | -$10 | $0 | $0 |
| % Margin | – | – | – | – |